ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · IEX Real-Time Price · USD
6.55
+0.11 (1.71%)
At close: Apr 26, 2024, 4:00 PM
6.62
+0.07 (1.07%)
After-hours: Apr 26, 2024, 7:55 PM EDT
ADMA Biologics Revenue
In the year 2023, ADMA Biologics had annual revenue of $258.22M with 67.59% growth. Revenue in the quarter ending December 31, 2023 was $73.90M with 47.86% year-over-year growth.
Revenue (ttm)
$258.22M
Revenue Growth
+67.59%
P/S Ratio
5.88
Revenue / Employee
$413,806
Employees
624
Market Cap
1.52B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 258.22M | 104.14M | 67.59% |
Dec 31, 2022 | 154.08M | 73.14M | 90.36% |
Dec 31, 2021 | 80.94M | 38.72M | 91.72% |
Dec 31, 2020 | 42.22M | 12.87M | 43.85% |
Dec 31, 2019 | 29.35M | 12.36M | 72.79% |
Dec 31, 2018 | 16.99M | -5.78M | -25.37% |
Dec 31, 2017 | 22.76M | 12.10M | 113.49% |
Dec 31, 2016 | 10.66M | 3.48M | 48.53% |
Dec 31, 2015 | 7.18M | 1.26M | 21.34% |
Dec 31, 2014 | 5.92M | 2.85M | 92.84% |
Dec 31, 2013 | 3.07M | 1.95M | 174.35% |
Dec 31, 2012 | 1.12M | 357.08K | 46.92% |
Dec 31, 2011 | 761.04K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Addus HomeCare | 1.06B |
Warby Parker | 669.77M |
U.S. Physical Therapy | 604.80M |
InMode | 492.05M |
Veracyte | 361.05M |
Zai Lab | 266.72M |
Dynavax Technologies | 232.28M |
LeMaitre Vascular | 193.48M |
ADMA News
- 6 weeks ago - ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM® - GlobeNewsWire
- 7 weeks ago - ADMA Biologics to Participate in the Raymond James Institutional Investor Conference - GlobeNewsWire
- 2 months ago - ADMA Biologics Announces CFO Transition - GlobeNewsWire
- 2 months ago - ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 - GlobeNewsWire
- 2 months ago - ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics - GlobeNewsWire
- 3 months ago - ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update - GlobeNewsWire
- 4 months ago - ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management - GlobeNewsWire